Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

IDEC/GENENTECH RITUXAN NON-HODGKIN'S LYMPHOMA RESPONDERS: HALF IN REMISSION AT ONE YEAR; FIRST-LINE AND COMBINATION CHEMOTHERAPY STUDIES WITH MAB PLANNED

Executive Summary

Half of the responders to Idec/Genentech's Rituxan for non-Hodgkin's lymphoma remain in remission, Idec said July 25 following a favorable review by FDA's Biological Response Modifiers Advisory Committee. Of 80 responders in the Rituxan pivotal trial, 38 are still in remission 11.8 months following treatment.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS030577

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel